After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only.
CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses
Now.. What would be the result here, if BioDirection's NanoDx was the next big thing in testing, adopted from 31st December onwards??
Ahh but just give me the EUA for the single test and I'll be happy!
SE1 Price at posting:
3.2¢ Sentiment: Buy Disclosure: Held